In situ localization of HuHF serine protease mRNA and cytotoxic cell-associated antigens in human dermatoses. A novel method for the detection of cytotoxic cells in human tissues.

Department of Dermatology, Stanford University School of Medicine, California.
American Journal Of Pathology (Impact Factor: 4.6). 12/1988; 133(2):218-25.
Source: PubMed

ABSTRACT Human Hanukah Factor (HuHF) is a trypsinlike serine protease associated with cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells. Employing a radiolabeled RNA probe for the HuHF gene, cells containing HuHF mRNA in situ were detected in skin lesions from patients with a variety of reactive and neoplastic dermatoses including positive allergic contact dermatitis patch tests, lichen planus, erythrodermic psoriasis, Sezary syndrome, and poikilodermatous mycosis fungoides. The results were correlated with in situ studies of CTL/NK subsets as defined immunohistologically by a panel of monoclonal antibodies applied to sermiserial sections of the same tissue blocks used for the HuHF hybridizations. The results suggest that cytotoxic cells are present in each of these dermatoses, that they may be situated within either the epidermis or the dermis, and that they belong predominantly to the CTL subset because Leu-7+ or CD16+ cells (NK cells) were typically rare or absent. A variable proportion of cells expressed Leu-19 antigen (a marker for non-MHC-restricted cytotoxic cells); however, its rarity in several cases suggests that most of the HuHF+ cells identified in them belonged to the MHC-restricted, Leu-19- CTL subset. It is concluded that the correlation of molecular biologic and immunohistologic data will be a useful method for the further characterization of cytotoxic cell subsets in human dermatoses.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Lymphocytes from the synovial fluid of patients with rheumatoid arthritis were examined for the expression of granzyme A and perforin. Previous studies have demonstrated that the expression of these proteins, which are implicated as mediators of cytotoxicity, can be used to identify putative cytolytic lymphocytes in vivo. Twenty-two synovial fluid samples were analyzed by in situ hybridization and immunohistochemistry. In six patients receiving low doses of immunosuppressant, a population of granzyme A- and perforin-expressing lymphocytes could be identified. In contrast, lymphocytes from patients who were receiving high doses of immunosuppressant did not contain any granzyme A- or perforin-expressing lymphocytes. Synovial fluid lymphocytes from patients with osteoarthritis did not express either marker. The expression of these markers demonstrates the presence of potentially functional cytolytic lymphocytes, expressing proteins required to mediate killing, in the synovial fluid of patients with rheumatoid arthritis. This suggests that cytolytic lymphocytes may be involved in the pathogenesis of rheumatoid arthritis.
    Proceedings of the National Academy of Sciences 02/1992; 89(2):549-53. DOI:10.1073/pnas.89.2.549 · 9.81 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To understand the role of cytolytic lymphocytes in the pathogenesis of rheumatoid arthritis, we investigated the expression of lymphocyte cytotoxicity mediators, perforin, and serine esterases, in lymphocytes derived from the synovial fluid of 15 patients with rheumatoid arthritis. Previous work has shown that CD8+ lymphocytes that possess markers of activation appear to be present in rheumatoid arthritis (RA). By means of in situ hybridization techniques and immunohistochemical analysis, the authors show that perforin and two serine esterases (serine esterase 1/Hanukah factor/granzyme A, and serine esterase 2/granzyme B) are expressed by subpopulations of CD8+ and CD56+ lymphocytes obtained from synovial fluid. The presence of these cytotoxic mediators suggests a possible mechanism for tissue damage, and provides evidence implicating cytolytic lymphocytes in the pathogenesis of RA.
    American Journal Of Pathology 06/1992; 140(5):1261-8. · 4.60 Impact Factor
  • Springer Seminars in Immunopathology 08/1998; 19(3):323-343. DOI:10.1007/BF00787229 · 4.55 Impact Factor


1 Download
Available from